EUVIMEDEUVIMED entdecken
LeserbriefKommentar

Reply to “promising modality for severe ulcerative colitis: infliximab and plant-based diet as first-line (IPF) therapy”

Makoto Naganuma iD

Journal of Gastroenterology · 2024

DOI: 10.1007/s00535-024-02113-y ↗

Kurz gefasst

Leserbrief in der Zeitschrift Journal of Gastroenterology, 2024. Verfasst von Makoto Naganuma. Beteiligte Einrichtung: Third Department of Internal Medicine, Division of Gastroenterology and Hepatology, Kansai Medical University, 2-5-1 Shinmachi, Hirakata, Osaka, 573-…. Hauptthemen laut MEDLINE: Infliximab, Colitis, Ulcerative, Gastrointestinal Agents. Die Arbeit nennt 4 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InfliximabColitis, UlcerativeGastrointestinal AgentsHumansDiet, VegetarianSeverity of Illness IndexDiet, Plant-Based

Substanzen

InfliximabGastrointestinal Agents

Autor:innen und Institutionen

  • Third Department of Internal Medicine, Division of Gastroenterology and Hepatology, Kansai Medical University, 2-5-1 Shinmachi, Hirakata, Osaka, 573-1010, Japan. naganuma@hirakata.kmu.ac.jp.

ORCID-Profile: Makoto Naganuma

Zitieren

APA

Naganuma, M. (2024). Reply to “promising modality for severe ulcerative colitis: infliximab and plant-based diet as first-line (IPF) therapy”. Journal of Gastroenterology. https://doi.org/10.1007/s00535-024-02113-y

Vancouver

Naganuma M. Reply to “promising modality for severe ulcerative colitis: infliximab and plant-based diet as first-line (IPF) therapy”. Journal of Gastroenterology. 2024. doi:10.1007/s00535-024-02113-y

BibTeX
@article{Naganuma2024,
  author = {Naganuma, Makoto},
  title = {Reply to “promising modality for severe ulcerative colitis: infliximab and plant-based diet as first-line (IPF) therapy”},
  journal = {Journal of Gastroenterology},
  year = {2024},
  doi = {10.1007/s00535-024-02113-y}
}
Kostenlos starten →